Recent Analysts’ Ratings Updates for Establishment Labs (ESTA)

A number of research firms have changed their ratings and price targets for Establishment Labs (NASDAQ: ESTA):

• 2/26/2026 – Establishment Labs had its price target raised by Canaccord Genuity Group Inc. from $85.00 to $90.00. They now have a “buy” rating on the stock.
• 2/25/2026 – Establishment Labs had its price target raised by Mizuho from $90.00 to $100.00. They now have an “outperform” rating on the stock.
• 2/25/2026 – Establishment Labs had its price target raised by Stephens from $85.00 to $90.00. They now have an “overweight” rating on the stock.
• 2/24/2026 – Establishment Labs had its price target raised by BTIG Research from $86.00 to $88.00. They now have a “buy” rating on the stock.
• 2/24/2026 – Establishment Labs had its price target raised by Needham & Company LLC from $84.00 to $86.00. They now have a “buy” rating on the stock.
• 1/12/2026 – Establishment Labs had its “buy” rating reaffirmed by Needham & Company LLC. They now have a $84.00 price target on the stock.

Establishment Labs Holdings Inc is a global medical technology company specializing in the design, development and manufacture of silicone gel breast implants for aesthetic and reconstructive surgery. The company’s proprietary portfolio is built around patient-focused safety, customization and innovation, offering solutions intended to enhance surgical outcomes and support clinical traceability.

The company’s flagship products fall under the Motiva® brand, which includes a range of ergonomic and round breast implants featuring SilkSurface® texturing and an embedded Q Inside® Safety microtransponder for unique implant identification.